Dae-Hyun Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dae-Hyun Kim has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
- Jae-Kwan Cha
Department of Neurology, Dong-A University Hospital, Busan, Republic of Korea
35 shared publications - Hee-Joon Bae
Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
34 shared publications - Beom Joon Kim
Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea
33 shared publications - Joon-Tae Kim
Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
33 shared publications - Jay Chol Choi
Department of Neurology, Jeju National University Hospital, Jeju National University College of Medicine, Jeju-si, Republic of Korea
32 shared publications - Dong-Ick Shin
Department of Neurology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea
29 shared publications
Latest Publications
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218546
Vascular Imaging Features and Time-Specific Recurrence Risk After Craniocervical Artery Dissection
Background and ObjectivesCraniocervical artery dissection (CCAD) is a major cause of stroke in young adults, yet its recurrence risk remains poorly defined because of delayed enrollment in prior re...
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7) , e218546
Vascular Imaging Features and Time-Specific Recurrence Risk After Craniocervical Artery Dissection
Background and ObjectivesCraniocervical artery dissection (CCAD) is a major cause of stroke in young adults, yet its recurrence risk remains poorly defined because of delayed enrollment in prior re...
- Open Access
Stalled Outcome Gains Despite Treatment Intensification in Stroke Patients Aged 80 and Older: A 12-Year Cohort Study
Background Adults aged 80 years and older are the fastest-growing segment of the stroke population. Whether contemporary advances in stroke care have produced sustained outcome gains in this group during the past decade, including the post-pandemic era, has not been examined in nationwide longitudinal data with concurrent age-specific comparison. Methods Using the Clinical Research Collaboration for Stroke in Korea-National Institutes of Health (CRCS-K-NIH) registry, we analyzed consecutive adults with acute ischemic stroke admitted within 7 days of symptom onset between 2011 and 2022. Patients aged 80 years and older formed the primary cohort; those aged 18-79 years served as comparators. Primary outcomes were 3-month utility-weighted modified Rankin Scale (UW-mRS) and 1-year all-cause mortality. Non-linear trends and age-group-by-year interaction were modeled using restricted cubic splines adjusted for sex, age, and baseline NIHSS. Results Of 83,953 patients, 18,514 (22.1%) were aged 80 years and older; their proportion rose from 17.4% to 27.3%. Despite treatment intensification (endovascular thrombectomy 4.2% to 10.6%; oral anticoagulation for atrial fibrillation 52.5% to 76.9%), 1-year mortality in this group fell from 27.5% in 2011 to 19.4% in 2019, then rose to 23.7% by 2022; 3-month UW-mRS improved from 0.47 to 0.51 over the same period, then stagnated at 0.48. Restricted cubic splines confirmed significant nonlinearity in both outcomes after adjustment for sex, age, and NIHSS (P < 0.01 for both). Younger patients showed no comparable functional deterioration. Age-group-by-year interaction was significant for 3-month UW-mRS (P < 0.001) but not for 1-year mortality (P = 0.058), which showed a similar direction in both age groups. Conclusion In this nationwide registry, patients aged 80 years and older experienced an age-specific inflection of functional recovery gains after 2019 despite continued intensification of acute stroke care. Sustaining outcome gains in this population may require attention to post-acute care infrastructure.
Open AccessStalled Outcome Gains Despite Treatment Intensification in Stroke Patients Aged 80 and Older: A 12-Year Cohort Study
Background Adults aged 80 years and older are the fastest-growing segment of the stroke population. Whether contemporary advances in stroke care have produced sustained outcome gains in this group during the past decade, including the post-pandemic era, has not been examined in nationwide longitudinal data with concurrent age-specific comparison. Methods Using the Clinical Research Collaboration for Stroke in Korea-National Institutes of Health (CRCS-K-NIH) registry, we analyzed consecutive adults with acute ischemic stroke admitted within 7 days of symptom onset between 2011 and 2022. Patients aged 80 years and older formed the primary cohort; those aged 18-79 years served as comparators. Primary outcomes were 3-month utility-weighted modified Rankin Scale (UW-mRS) and 1-year all-cause mortality. Non-linear trends and age-group-by-year interaction were modeled using restricted cubic splines adjusted for sex, age, and baseline NIHSS. Results Of 83,953 patients, 18,514 (22.1%) were aged 80 years and older; their proportion rose from 17.4% to 27.3%. Despite treatment intensification (endovascular thrombectomy 4.2% to 10.6%; oral anticoagulation for atrial fibrillation 52.5% to 76.9%), 1-year mortality in this group fell from 27.5% in 2011 to 19.4% in 2019, then rose to 23.7% by 2022; 3-month UW-mRS improved from 0.47 to 0.51 over the same period, then stagnated at 0.48. Restricted cubic splines confirmed significant nonlinearity in both outcomes after adjustment for sex, age, and NIHSS (P < 0.01 for both). Younger patients showed no comparable functional deterioration. Age-group-by-year interaction was significant for 3-month UW-mRS (P < 0.001) but not for 1-year mortality (P = 0.058), which showed a similar direction in both age groups. Conclusion In this nationwide registry, patients aged 80 years and older experienced an age-specific inflection of functional recovery gains after 2019 despite continued intensification of acute stroke care. Sustaining outcome gains in this population may require attention to post-acute care infrastructure.
- Open Access
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e048491
Comprehensive Prestroke Risk Factor Control and Functional Outcomes After Acute Ischemic Stroke
Background: Whether comprehensive prestroke risk factor (RF) management—defined by the extent to which existing major RFs meet prespecified treatment and biomarker criteria—is associated with 3‐month functional outcomes after ischemic stroke remains unclear. Methods: We analyzed patients with ischemic stroke from the CRCS‐K‐NIH (Clinical Research Collaborations for Stroke in Korea‐National Institutes for Health) registry (2011–2022), a multicenter stroke registry in Korea. Hypertension, diabetes, dyslipidemia, and atrial fibrillation were considered as major RFs for ischemic stroke. Comprehensive prestroke RF management was categorized as well controlled (all present RFs meeting study‐defined control criteria), partially controlled (some RFs meeting this criteria), or poorly controlled (no RFs meeting this criteria). The primary outcome was 3‐month modified Rankin Scale score of 0 to 2, indicating functional independence (good outcome). Results: Among 63 570 patients with ≥1 major RFs, 28.6% were poorly controlled, 35.6% partially controlled, and 35.8% well controlled. The rate of 3‐month good outcome was 66.0% among those with 1 RF, 60.8% in 2, and 55.0% in ≥3. After multivariable adjustment, both well‐controlled and partially controlled groups had significantly higher odds of achieving good 3‐month outcomes compared with poorly controlled patients, consistently across RF burden strata(well controlled: adjusted odds ratio, 1.16 [95% CI, 1.08–1.25] for 1 RF, 1.34 [95% CI, 1.21–1.48] for 2, and 1.23 [95% CI, 1.03–1.48] for ≥3; partially controlled: 1.16 [95% CI, 1.06–1.26] for 2; 1.22 [95% CI, 1.05–1.42] for ≥3) and in the overall cohort (well controlled: 1.22 [95% CI, 1.15–1.29], partially controlled: 1.14 [95% CI, 1.07–1.22]). Conclusions: Comprehensive prestroke RF management, defined by study‐specific treatment‐ and biomarker‐based criteria, was independently associated with a higher likelihood of favorable 3‐month outcomes across levels of RF burden. These findings suggest that effective prestroke management of existing RFs may improve poststroke functional outcomes, regardless of the number of RFs present.
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e048491
Open AccessComprehensive Prestroke Risk Factor Control and Functional Outcomes After Acute Ischemic Stroke
Background: Whether comprehensive prestroke risk factor (RF) management—defined by the extent to which existing major RFs meet prespecified treatment and biomarker criteria—is associated with 3‐month functional outcomes after ischemic stroke remains unclear. Methods: We analyzed patients with ischemic stroke from the CRCS‐K‐NIH (Clinical Research Collaborations for Stroke in Korea‐National Institutes for Health) registry (2011–2022), a multicenter stroke registry in Korea. Hypertension, diabetes, dyslipidemia, and atrial fibrillation were considered as major RFs for ischemic stroke. Comprehensive prestroke RF management was categorized as well controlled (all present RFs meeting study‐defined control criteria), partially controlled (some RFs meeting this criteria), or poorly controlled (no RFs meeting this criteria). The primary outcome was 3‐month modified Rankin Scale score of 0 to 2, indicating functional independence (good outcome). Results: Among 63 570 patients with ≥1 major RFs, 28.6% were poorly controlled, 35.6% partially controlled, and 35.8% well controlled. The rate of 3‐month good outcome was 66.0% among those with 1 RF, 60.8% in 2, and 55.0% in ≥3. After multivariable adjustment, both well‐controlled and partially controlled groups had significantly higher odds of achieving good 3‐month outcomes compared with poorly controlled patients, consistently across RF burden strata(well controlled: adjusted odds ratio, 1.16 [95% CI, 1.08–1.25] for 1 RF, 1.34 [95% CI, 1.21–1.48] for 2, and 1.23 [95% CI, 1.03–1.48] for ≥3; partially controlled: 1.16 [95% CI, 1.06–1.26] for 2; 1.22 [95% CI, 1.05–1.42] for ≥3) and in the overall cohort (well controlled: 1.22 [95% CI, 1.15–1.29], partially controlled: 1.14 [95% CI, 1.07–1.22]). Conclusions: Comprehensive prestroke RF management, defined by study‐specific treatment‐ and biomarker‐based criteria, was independently associated with a higher likelihood of favorable 3‐month outcomes across levels of RF burden. These findings suggest that effective prestroke management of existing RFs may improve poststroke functional outcomes, regardless of the number of RFs present.
- Open Access
Post-Discharge Exposure to Ambient Sulfur Dioxide is Associated with Increased Risk of Stroke Recurrence
Background and Purpose: Ambient air pollution is an established risk factor for incident stroke, but whether post-discharge pollutant exposure influences stroke recurrence remains unknown. We investigated the association between post-discharge exposure to six ambient air pollutants and stroke recurrence in patients with acute ischemic stroke. Methods: We analyzed data from 27,346 patients in the CRCS-K-NIH nationwide multicenter registry of acute ischemic stroke patients (2014–2021) with confirmed ischemic stroke, residential address data, and matched air quality records. The primary exposure was the 3-month post-discharge average concentration of PM 10 , PM 2.5 , NO₂, SO₂, CO, and O₃, assessed at the district level using inverse-distance weighted interpolation. The primary outcome was stroke recurrence from 3 to 15 months post-discharge. Cause-specific Cox proportional hazards models accounting for the multilevel data structure were used, with all-cause mortality as a competing risk. Restricted cubic splines assessed nonlinear dose-response relationships. Results: During follow-up (median 364.8 days), 765 patients experienced stroke recurrence and 471 died. Among the six pollutants, only SO₂ showed a statistically significant association with recurrence (P for overall association in the restricted cubic spline analysis = 0.024). A potential threshold was identified at approximately 8.2 ppb, above which recurrence risk increased progressively (P for non-linearity = 0.095). The association was numerically stronger among older adults (≥75 years; P for interaction = 0.051) and women (P for interaction = 0.062). The highest SO₂ concentrations were observed in harbor cities (Incheon, Ulsan, Busan), consistent with maritime shipping emissions. No significant associations were observed for the other five pollutants. Conclusions: Elevated post-discharge SO₂ exposure is associated with increased stroke recurrence risk, particularly in harbor regions and among older adults and women. These findings support incorporating ambient air quality monitoring into secondary stroke prevention strategies.
Open AccessPost-Discharge Exposure to Ambient Sulfur Dioxide is Associated with Increased Risk of Stroke Recurrence
Background and Purpose: Ambient air pollution is an established risk factor for incident stroke, but whether post-discharge pollutant exposure influences stroke recurrence remains unknown. We investigated the association between post-discharge exposure to six ambient air pollutants and stroke recurrence in patients with acute ischemic stroke. Methods: We analyzed data from 27,346 patients in the CRCS-K-NIH nationwide multicenter registry of acute ischemic stroke patients (2014–2021) with confirmed ischemic stroke, residential address data, and matched air quality records. The primary exposure was the 3-month post-discharge average concentration of PM 10 , PM 2.5 , NO₂, SO₂, CO, and O₃, assessed at the district level using inverse-distance weighted interpolation. The primary outcome was stroke recurrence from 3 to 15 months post-discharge. Cause-specific Cox proportional hazards models accounting for the multilevel data structure were used, with all-cause mortality as a competing risk. Restricted cubic splines assessed nonlinear dose-response relationships. Results: During follow-up (median 364.8 days), 765 patients experienced stroke recurrence and 471 died. Among the six pollutants, only SO₂ showed a statistically significant association with recurrence (P for overall association in the restricted cubic spline analysis = 0.024). A potential threshold was identified at approximately 8.2 ppb, above which recurrence risk increased progressively (P for non-linearity = 0.095). The association was numerically stronger among older adults (≥75 years; P for interaction = 0.051) and women (P for interaction = 0.062). The highest SO₂ concentrations were observed in harbor cities (Incheon, Ulsan, Busan), consistent with maritime shipping emissions. No significant associations were observed for the other five pollutants. Conclusions: Elevated post-discharge SO₂ exposure is associated with increased stroke recurrence risk, particularly in harbor regions and among older adults and women. These findings support incorporating ambient air quality monitoring into secondary stroke prevention strategies.
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (2)
Sex-Based Differences in Disease Burden and Phenotype in CADASIL
Previous studies have reported mixed findings regarding sex differences in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), with some indicating earlier ischemic events in men, whereas others found no significant difference in stroke onset. However, evidence from Asian populations remains limited, where clinical manifestations and NOTCH3 variant distribution differ substantially from those in European cohorts. We investigated sex-specific variations in clinical phenotypes and brain MRI characteristics among Korean patients with CADASIL. In this nationwide retrospective study, 577 patients were screened for CADASIL across 26 centers in South Korea. After excluding those with benign or uncertain variants or insufficient clinical or MRI data, 368 individuals with pathogenic NOTCH3 variants were included in the final analysis. Clinical features, vascular risk factors, and NOTCH3 variant positions classified by epidermal growth factor–like repeat (EGFr) domains were compared between sexes. Brain MRI findings—including white matter hyperintensities (WMHs), lacunes, cerebral microbleeds, and atrophy—were evaluated. Sex differences in the onset of ischemic stroke and dementia were analyzed using Kaplan-Meier and Cox proportional hazards models. The mean age of the patients at data collection was 61.7 ± 11.9 years, and 48.6% were male. Thirty-six distinct pathogenic variants were identified. The most frequent variant was R544C (40.8%) located at the EGFr 13/14 interdomain boundary (corresponding to exon 11). Other recurrent variants were R75P (17.9%), C542R (5.4%), and R587C (4.6%). Men exhibited a higher prevalence of ischemic stroke (70.9% vs 44.4%, p < 0.001) and experienced their first event at an earlier age (median 53 vs 59 years, log-rank p < 0.001). On brain MRI, male sex was independently associated with a greater lacune burden (odds ratio 3.03, 95% CI 1.70–5.38, p < 0.001) while female sex tended to show higher WMH volume. This nationwide study highlights distinct sex differences in CADASIL presentation within a Korean population. Male patients exhibited a higher prevalence and earlier onset of ischemic stroke not fully explained by conventional vascular risk factors. These findings underscore the importance of integrating sex, hormonal, and genetic-epigenetic factors into future research to guide precision phenotyping and sex-informed clinical management in CADASIL.
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (2)
Open AccessSex-Based Differences in Disease Burden and Phenotype in CADASIL
Previous studies have reported mixed findings regarding sex differences in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), with some indicating earlier ischemic events in men, whereas others found no significant difference in stroke onset. However, evidence from Asian populations remains limited, where clinical manifestations and NOTCH3 variant distribution differ substantially from those in European cohorts. We investigated sex-specific variations in clinical phenotypes and brain MRI characteristics among Korean patients with CADASIL. In this nationwide retrospective study, 577 patients were screened for CADASIL across 26 centers in South Korea. After excluding those with benign or uncertain variants or insufficient clinical or MRI data, 368 individuals with pathogenic NOTCH3 variants were included in the final analysis. Clinical features, vascular risk factors, and NOTCH3 variant positions classified by epidermal growth factor–like repeat (EGFr) domains were compared between sexes. Brain MRI findings—including white matter hyperintensities (WMHs), lacunes, cerebral microbleeds, and atrophy—were evaluated. Sex differences in the onset of ischemic stroke and dementia were analyzed using Kaplan-Meier and Cox proportional hazards models. The mean age of the patients at data collection was 61.7 ± 11.9 years, and 48.6% were male. Thirty-six distinct pathogenic variants were identified. The most frequent variant was R544C (40.8%) located at the EGFr 13/14 interdomain boundary (corresponding to exon 11). Other recurrent variants were R75P (17.9%), C542R (5.4%), and R587C (4.6%). Men exhibited a higher prevalence of ischemic stroke (70.9% vs 44.4%, p < 0.001) and experienced their first event at an earlier age (median 53 vs 59 years, log-rank p < 0.001). On brain MRI, male sex was independently associated with a greater lacune burden (odds ratio 3.03, 95% CI 1.70–5.38, p < 0.001) while female sex tended to show higher WMH volume. This nationwide study highlights distinct sex differences in CADASIL presentation within a Korean population. Male patients exhibited a higher prevalence and earlier onset of ischemic stroke not fully explained by conventional vascular risk factors. These findings underscore the importance of integrating sex, hormonal, and genetic-epigenetic factors into future research to guide precision phenotyping and sex-informed clinical management in CADASIL.
- Open Access
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5)
Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation‐Related Stroke
Background: This study aimed to describe the temporal evolution of antithrombotic treatment strategies and associated clinical outcomes after atrial fibrillation‐related acute ischemic stroke. Methods: This multicenter prospective cohort study enrolled patients with acute ischemic stroke and atrial fibrillation from 16 tertiary stroke centers across South Korea between February 2018 and January 2021, with follow‐up completed by January 2022. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all‐cause death. Secondary outcomes included individual components of the primary outcome and major bleeding events. Results: The median follow‐up duration was 1.92 years. Among 2965 patients (mean±SD age, 75.3 [10.2] years; 54.1% male), antithrombotic strategies varied widely in the acute phase. Within 48 hours of admission, 50.9% received antiplatelet‐only therapy (29.4% single, 21.5% dual), 23.2% received non–vitamin K antagonist oral anticoagulant monotherapy, and 10.4% received a combination of antiplatelets and anticoagulants. By discharge, non–vitamin K antagonist oral anticoagulant monotherapy had become the predominant treatment strategy (65.7%), and this pattern persisted throughout follow‐up. The incidence of the primary end point was highest in the first 2 weeks (32.70 [95% CI, 29.64–36.06] per 100 person‐months) and declined thereafter. Across all time periods, patients receiving non–vitamin K antagonist oral anticoagulant monotherapy consistently had lower incidence rates (3‐month rate, 4.95 [95% CI, 4.37–5.61] per 100 person‐months) than those receiving antiplatelet‐only therapy (11.98 [95% CI, 9.57–15.01]) or no antithrombotic therapy (18.44 [95% CI, 14.26–23.86]). Conclusions: In this prospective cohort of patients with atrial fibrillation‐related stroke, early antithrombotic treatment strategies were heterogeneous but evolved primarily toward use of non–vitamin K antagonist oral anticoagulant monotherapy. Treatment selection was associated with marked differences in outcomes, particularly during the early high‐risk period.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5)
Open AccessTemporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation‐Related Stroke
Background: This study aimed to describe the temporal evolution of antithrombotic treatment strategies and associated clinical outcomes after atrial fibrillation‐related acute ischemic stroke. Methods: This multicenter prospective cohort study enrolled patients with acute ischemic stroke and atrial fibrillation from 16 tertiary stroke centers across South Korea between February 2018 and January 2021, with follow‐up completed by January 2022. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all‐cause death. Secondary outcomes included individual components of the primary outcome and major bleeding events. Results: The median follow‐up duration was 1.92 years. Among 2965 patients (mean±SD age, 75.3 [10.2] years; 54.1% male), antithrombotic strategies varied widely in the acute phase. Within 48 hours of admission, 50.9% received antiplatelet‐only therapy (29.4% single, 21.5% dual), 23.2% received non–vitamin K antagonist oral anticoagulant monotherapy, and 10.4% received a combination of antiplatelets and anticoagulants. By discharge, non–vitamin K antagonist oral anticoagulant monotherapy had become the predominant treatment strategy (65.7%), and this pattern persisted throughout follow‐up. The incidence of the primary end point was highest in the first 2 weeks (32.70 [95% CI, 29.64–36.06] per 100 person‐months) and declined thereafter. Across all time periods, patients receiving non–vitamin K antagonist oral anticoagulant monotherapy consistently had lower incidence rates (3‐month rate, 4.95 [95% CI, 4.37–5.61] per 100 person‐months) than those receiving antiplatelet‐only therapy (11.98 [95% CI, 9.57–15.01]) or no antithrombotic therapy (18.44 [95% CI, 14.26–23.86]). Conclusions: In this prospective cohort of patients with atrial fibrillation‐related stroke, early antithrombotic treatment strategies were heterogeneous but evolved primarily toward use of non–vitamin K antagonist oral anticoagulant monotherapy. Treatment selection was associated with marked differences in outcomes, particularly during the early high‐risk period.
- Open Access
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e046592
Annual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea
Background: This study aimed to evaluate secular trends in the control of major risk factors at the time of ischemic stroke to assess the real‐world implementation of prevention guidelines and identify areas needing greater clinical attention for improved early stroke outcomes. Methods: We retrospectively analyzed data from a prospective, multicenter, nationwide registry of consecutive patients with acute ischemic stroke between 2011 and 2022. For risk factor controls of interest, hypertension, diabetes, dyslipidemia, and atrial fibrillation (AF) were considered. Well‐controlled risk factors were defined as follows: “well‐controlled hypertension”: hypertension with prior antihypertensive medication and systolic blood pressure P trend P trend <0.001). Conclusions: Our study confirmed a continuous increase in prestroke risk factor control, including diabetes, dyslipidemia, and AF, but the rate remained suboptimal at stroke onset. These findings may help inform strategies to improve risk factor management by identifying priority areas that warrant targeted intervention in clinical practice and population‐level guidelines.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e046592
Open AccessAnnual Trends in Risk Factor Control Status at the Time of Ischemic Stroke in South Korea
Background: This study aimed to evaluate secular trends in the control of major risk factors at the time of ischemic stroke to assess the real‐world implementation of prevention guidelines and identify areas needing greater clinical attention for improved early stroke outcomes. Methods: We retrospectively analyzed data from a prospective, multicenter, nationwide registry of consecutive patients with acute ischemic stroke between 2011 and 2022. For risk factor controls of interest, hypertension, diabetes, dyslipidemia, and atrial fibrillation (AF) were considered. Well‐controlled risk factors were defined as follows: “well‐controlled hypertension”: hypertension with prior antihypertensive medication and systolic blood pressure P trend P trend <0.001). Conclusions: Our study confirmed a continuous increase in prestroke risk factor control, including diabetes, dyslipidemia, and AF, but the rate remained suboptimal at stroke onset. These findings may help inform strategies to improve risk factor management by identifying priority areas that warrant targeted intervention in clinical practice and population‐level guidelines.
- 1 March 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (3) , 673-683
Timing of Initiation and Efficacy of Dual Antiplatelet Therapy in Minor Stroke or High-Risk TIA
BACKGROUND: Dual antiplatelet therapy (DAPT) is recommended within 24 hours for patients with minor ischemic stroke or high-risk transient ischemic attack. However, the optimal timing for initiating DAPT remains unclear. METHODS: From a prospective multicenter cohort involving 20 stroke centers between January 2011 and April 2023, patients with minor noncardioembolic ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischemic attack who presented within 7 days of symptom onset were included. We evaluated outcomes based on in-hospital initiation of DAPT versus monotherapy (aspirin or clopidogrel alone). The primary outcome was a composite of recurrent stroke, myocardial infarction, and death within 90 days. Patients were grouped by time from symptom onset to hospital arrival: 0 to 24 hours, 24 to 72 hours, and >72 hours. Time-to-treatment effects were analyzed using Cox proportional hazards models, with inverse probability of treatment weighting based on propensity scores. The adjusted models incorporated demographic factors, baseline clinical characteristics, vascular risk factors, stroke subtype, relevant arterial status, and prior antiplatelet use. RESULTS: Among the 41 530 patients (mean age, 66.3 years; 25 771 [62%] male), 25 112 (60.5%) received DAPT. The 90-day primary outcome occurred in 2663 (10.7%) of the DAPT group versus 1900 (11.6%) in the monotherapy group (hazard ratio, 0.82 [95% CI, 0.77–0.87]). The benefit of DAPT was most pronounced when initiated within 24 hours (hazard ratio, 0.74 [95% CI, 0.69–0.79]). No significant benefit was observed when DAPT was initiated between 24 and 72 hours (hazard ratio, 1.00 [95% CI, 0.88–1.15]), and a higher risk was suggested for initiation beyond 72 hours (hazard ratio, 1.25 [95% CI, 1.01–1.55]). Time-dependent analysis showed a benefit crossing the null at ≈42 hours. CONCLUSIONS: Early initiation of DAPT was associated with the greatest clinical benefit, consistent with current guideline recommendations. The therapeutic effect appeared to decline progressively beyond this period, with an estimated threshold around 42 hours.
- 1 March 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (3) , 673-683
Timing of Initiation and Efficacy of Dual Antiplatelet Therapy in Minor Stroke or High-Risk TIA
BACKGROUND: Dual antiplatelet therapy (DAPT) is recommended within 24 hours for patients with minor ischemic stroke or high-risk transient ischemic attack. However, the optimal timing for initiating DAPT remains unclear. METHODS: From a prospective multicenter cohort involving 20 stroke centers between January 2011 and April 2023, patients with minor noncardioembolic ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischemic attack who presented within 7 days of symptom onset were included. We evaluated outcomes based on in-hospital initiation of DAPT versus monotherapy (aspirin or clopidogrel alone). The primary outcome was a composite of recurrent stroke, myocardial infarction, and death within 90 days. Patients were grouped by time from symptom onset to hospital arrival: 0 to 24 hours, 24 to 72 hours, and >72 hours. Time-to-treatment effects were analyzed using Cox proportional hazards models, with inverse probability of treatment weighting based on propensity scores. The adjusted models incorporated demographic factors, baseline clinical characteristics, vascular risk factors, stroke subtype, relevant arterial status, and prior antiplatelet use. RESULTS: Among the 41 530 patients (mean age, 66.3 years; 25 771 [62%] male), 25 112 (60.5%) received DAPT. The 90-day primary outcome occurred in 2663 (10.7%) of the DAPT group versus 1900 (11.6%) in the monotherapy group (hazard ratio, 0.82 [95% CI, 0.77–0.87]). The benefit of DAPT was most pronounced when initiated within 24 hours (hazard ratio, 0.74 [95% CI, 0.69–0.79]). No significant benefit was observed when DAPT was initiated between 24 and 72 hours (hazard ratio, 1.00 [95% CI, 0.88–1.15]), and a higher risk was suggested for initiation beyond 72 hours (hazard ratio, 1.25 [95% CI, 1.01–1.55]). Time-dependent analysis showed a benefit crossing the null at ≈42 hours. CONCLUSIONS: Early initiation of DAPT was associated with the greatest clinical benefit, consistent with current guideline recommendations. The therapeutic effect appeared to decline progressively beyond this period, with an estimated threshold around 42 hours.
- Top Cited Papers
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (2) , 438-449
Management Strategies for Early Neurological Deterioration in Noncardioembolic Ischemic Stroke
BACKGROUND: Early neurological deterioration (END) is a frequent complication of acute ischemic stroke. Although END worsens clinical outcomes, standardized treatment strategies remain undefined, resulting in variability in clinical practice. This study examines real-world treatment patterns for END and compares the effects of different strategies on neurological and functional outcomes. METHODS: This study analyzed data from a nationwide, prospective, multicenter stroke registry in South Korea, including patients with noncardioembolic stroke who developed END due to stroke progression between January 2019 and August 2024. END was defined as new or worsening neurological symptoms meeting National Institutes of Health Stroke Scale criteria (≥2-point total or ≥1 point in consciousness or motor subscores) with radiological confirmation. Patients were classified into conservative management, antithrombotics change, and induced hypertension (iHTN). The primary outcomes were neurological improvement, defined as a ≥2-point reduction in the National Institutes of Health Stroke Scale score, and 3-month functional outcome measured by modified Rankin Scale ordinal shift. Secondary outcomes included good functional recovery (modified Rankin Scale score, 0–2) and composite vascular events (death, stroke, and myocardial infarction). Multivariable analyses adjusted for age, sex, prestroke modified Rankin Scale, initial National Institutes of Health Stroke Scale score, vascular risk factors, the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification, acute thrombolysis, and laboratory covariates. RESULTS: Among 3067 patients with END due to stroke progression, 1840 (60.0%) received conservative management, 747 (24.4%) underwent antithrombotic changes, and 480 (15.7%) were treated with iHTN. Neurological improvement occurred in 34.2% of patients, with the highest in the iHTN group (41.5%) compared with the conservative (32.2%) and antithrombotics change groups (34.4%; P <0.001). In adjusted analyses, iHTN increased the odds of neurological improvement (adjusted odds ratio, 1.55 [95% CI, 1.25–1.92]) and a favorable 3-month modified Rankin Scale shift (adjusted odds ratio, 1.24 95% CI, 1.03–1.48]) compared with conservative management, particularly in patients with large artery atherosclerosis. Antithrombotics change showed no significant association with neurological or functional recovery. CONCLUSIONS: In patients with noncardioembolic ischemic stroke who developed END due to stroke progression, iHTN was associated with favorable clinical outcomes.
- 1 February 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (2) , 438-449
Top Cited PapersManagement Strategies for Early Neurological Deterioration in Noncardioembolic Ischemic Stroke
BACKGROUND: Early neurological deterioration (END) is a frequent complication of acute ischemic stroke. Although END worsens clinical outcomes, standardized treatment strategies remain undefined, resulting in variability in clinical practice. This study examines real-world treatment patterns for END and compares the effects of different strategies on neurological and functional outcomes. METHODS: This study analyzed data from a nationwide, prospective, multicenter stroke registry in South Korea, including patients with noncardioembolic stroke who developed END due to stroke progression between January 2019 and August 2024. END was defined as new or worsening neurological symptoms meeting National Institutes of Health Stroke Scale criteria (≥2-point total or ≥1 point in consciousness or motor subscores) with radiological confirmation. Patients were classified into conservative management, antithrombotics change, and induced hypertension (iHTN). The primary outcomes were neurological improvement, defined as a ≥2-point reduction in the National Institutes of Health Stroke Scale score, and 3-month functional outcome measured by modified Rankin Scale ordinal shift. Secondary outcomes included good functional recovery (modified Rankin Scale score, 0–2) and composite vascular events (death, stroke, and myocardial infarction). Multivariable analyses adjusted for age, sex, prestroke modified Rankin Scale, initial National Institutes of Health Stroke Scale score, vascular risk factors, the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification, acute thrombolysis, and laboratory covariates. RESULTS: Among 3067 patients with END due to stroke progression, 1840 (60.0%) received conservative management, 747 (24.4%) underwent antithrombotic changes, and 480 (15.7%) were treated with iHTN. Neurological improvement occurred in 34.2% of patients, with the highest in the iHTN group (41.5%) compared with the conservative (32.2%) and antithrombotics change groups (34.4%; P <0.001). In adjusted analyses, iHTN increased the odds of neurological improvement (adjusted odds ratio, 1.55 [95% CI, 1.25–1.92]) and a favorable 3-month modified Rankin Scale shift (adjusted odds ratio, 1.24 95% CI, 1.03–1.48]) compared with conservative management, particularly in patients with large artery atherosclerosis. Antithrombotics change showed no significant association with neurological or functional recovery. CONCLUSIONS: In patients with noncardioembolic ischemic stroke who developed END due to stroke progression, iHTN was associated with favorable clinical outcomes.